Join leading scientists and innovators across Europe for a focused event exploring how cutting-edge translational strategies are shaping the next generation of biotherapeutics. The event will be hosted by our CEO, Rob Brainin, who looks forward to welcoming attendees and engaging with colleagues in person. Discover the latest approaches powering translational oncology, from advanced preclinical models and virtual biology to next‑generation antibodies and ADC innovation. This symposium brings together real-world examples that show how smarter experimental design, novel modalities, and translational insight are improving decision‑making from discovery through early clinical development.
Learn about and discuss:
- Durable tumour responses: Insights from MTAP‑deficient and advanced tumour models.
- Smarter preclinical decisions: Using virtual cells to scale translational decision‑making.
- Next‑generation ADCs & antibodies: Logic‑gated multispecific ADCs, novel linker‑payloads, and Phase 0 ROR1 learnings.
- Data that translates: Why model choice, annotation, and context matter.
- Understanding resistance: Translational insights from UNLOCK and beyond.
This symposium offers a unique opportunity to engage in high-quality scientific discussion in an expert-led setting, where the focus is on the development of next-generation cancer treatments.
